AHL
ALXO icon

Abel Hall LLC’s ALX Oncology ALXO Stock Holding History

Abel Hall LLC’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.3K Hold
12,598
– – 0.01% 784
2025
Q4 		$14.2K Hold
12,598
– – ﹤0.01% 709
2025
Q3 		$23.1K Sell
12,598
-2,611
-17% -$2.26K 0.01% 313
2025
Q2 		$6.31K Buy
+15,209
New +$7.68K ﹤0.01% 287
2025
Q1 		– Sell
-10,406
Closed -$17.4K – 205
2024
Q4 		$17.4K Buy
+10,406
New +$16K 0.01% 160

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Abel Hall LLC's ALXO Position: Q1 2026 in Review

Abel Hall LLC held its ALX Oncology (ALXO) position steady in Q1 2026 at 12,598 shares worth $25.3K. The position accounts for 0.01% of the portfolio, ranked #784.

Abel Hall LLC first reported a position in ALXO in Q4 2024 and has held it in 5 quarters since. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

  • Abel Hall LLC held 12,598 shares of ALX Oncology worth $25.3K as of Q1 2026.
  • Abel Hall LLC left its ALX Oncology share count unchanged in Q1 2026.
  • ALX Oncology made up 0.01% of Abel Hall LLC's portfolio in Q1 2026, its #784 holding.
  • Abel Hall LLC first reported a position in ALX Oncology in Q4 2024 and has held it in 5 quarters since.
  • 69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Abel Hall LLC's 13F filing for Q1 2026, filed 28 Apr 2026.